Literature DB >> 31145381

Resuscitative endovascular balloon occlusion of the aorta induced myocardial injury is mitigated by endovascular variable aortic control.

Carl A Beyer1, Guillaume L Hoareau, Emily M Tibbits, Anders J Davidson, Erik D DeSoucy, Meryl A Simon, John Kevin Grayson, Lucas P Neff, Timothy K Williams, Michael Austin Johnson.   

Abstract

BACKGROUND: The cardiac effects of resuscitative endovascular balloon occlusion of the aorta (REBOA) are largely unknown. We hypothesized that increased afterload from REBOA would lead to cardiac injury, and that partial flow using endovascular variable aortic control (EVAC) would mitigate this injury.
METHODS: Eighteen anesthetized swine underwent controlled 25% blood volume hemorrhage. Animals were randomized to either Zone 1 REBOA, Zone 1 EVAC, or no intervention (control) for 45 minutes. Animals were then resuscitated with shed blood, observed during critical care, and euthanized after a 6-hour total experimental time. Left ventricular function was measured with a pressure-volume catheter, and blood samples were drawn at routine intervals.
RESULTS: The average cardiac output during the intervention period was higher in the REBOA group (9.3 [8.6-15.4] L/min) compared with the EVAC group (7.2 [5.8-8.0] L/min, p = 0.01) and the control group (6.8 [5.8-7.7] L/min, p < 0.01). At the end of the intervention, the preload recruitable stroke work was significantly higher in both the REBOA and EVAC groups compared with the control group (111.2 [102.5-148.6] and 116.7 [116.6-141.4] vs. 67.1 [62.7-87.9], p = 0.02 and p < 0.01, respectively). The higher preload recruitable stroke work was maintained throughout the experiment in the EVAC group, but not in the REBOA group. Serum troponin concentrations after 6 hours were higher in the REBOA group compared with both the EVAC and control groups (6.26 ± 5.35 ng/mL vs 0.92 ± 0.61 ng/mL and 0.65 ± 0.38 ng/mL, p = 0.05 and p = 0.03, respectively). Cardiac intramural hemorrhage was higher in the REBOA group compared with the control group (1.67 ± 0.46 vs. 0.17 ± 0.18, p = 0.03), but not between the EVAC and control groups.
CONCLUSION: In a swine model of hemorrhagic shock, complete aortic occlusion resulted in cardiac injury, although there was no direct decrease in cardiac function. EVAC mitigated the cardiac injury and improved cardiac performance during resuscitation and critical care.

Entities:  

Mesh:

Year:  2019        PMID: 31145381     DOI: 10.1097/TA.0000000000002363

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  4 in total

1.  Automated aortic endovascular balloon volume titration prevents re-arrest immediately after return of spontaneous circulation in a swine model of nontraumatic cardiac arrest.

Authors:  Craig D Nowadly; M Austin Johnson; Scott T Youngquist; Timothy K Williams; Lucas P Neff; Guillaume L Hoareau
Journal:  Resusc Plus       Date:  2022-05-02

2.  Quantifying the need for pediatric REBOA: A gap analysis.

Authors:  Christina M Theodorou; A Francois Trappey; Carl A Beyer; Kaeli J Yamashiro; Shinjiro Hirose; Joseph M Galante; Alana L Beres; Jacob T Stephenson
Journal:  J Pediatr Surg       Date:  2020-09-22       Impact factor: 2.549

3.  REBOA as a New Damage Control Component in Hemodynamically Unstable Noncompressible Torso Hemorrhage Patients.

Authors:  Carlos A Ordoñez; Michael W Parra; Yaset Caicedo; Natalia Padilla; Fernando Rodríguez-Holguín; José Julián Serna; Alexander Salcedo; Alberto García; Claudia Orlas; Luis Fernando Pino; Ana Milena Del Valle; David Mejia; Juan Carlos Salamea-Molina; Megan Brenner; Tal Hörer
Journal:  Colomb Med (Cali)       Date:  2020-12-30

4.  Automated Partial Versus Complete Resuscitative Endovascular Balloon Occlusion of the Aorta for the Management of Hemorrhagic Shock in a Pig Model of Polytrauma: a Randomized Controlled Pilot Study.

Authors:  Guillaume L Hoareau; Carl A Beyer; Connor A Caples; Marguerite W Spruce; J Kevin Grayson; Lucas P Neff; Timothy K Williams; M Austin Johnson
Journal:  Mil Med       Date:  2020-12-30       Impact factor: 1.437

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.